Background: PALB2, the partner and localizer of BRCA2, binds directly to BRCA1 and is essential for homologous recombination repair and, henceforth, could influence the effect of docetaxel-cisplatin therapy. Previous studies have shown that PALB2 impedes the degradation of nuclear factor erythroid 2-related factor 2 (NRF2) through the binding and sequestration of its inhibitor Kelch-like ECH-associated protein (KEAP1). Over-expression of NRF2 could activate NOTCH signaling and lead to enrichment of cancer stem cells. In the current study, we examine the mRNA levels of PALB2 in advanced NSCLC p treated with docetaxel-cisplatin. Methods: We assessed PALB2 mRNA levels as potential biomarkers in tumor tissue from 177 cisplatin plus docetaxel-treated NSCLC p from the NCT00617656/ GECP-BREC trial. The relationship of the PALB2 mRNA levels with the PFS, OS and response were examined.
Results: Median age 62; 79.1% male; 51.4% adenocarcinoma. Results of PALB2 mRNA expression were as follows: PFS was 5.6 months (m) for p with high/ intermediate (H-I) PALB2 and 4.1 m for p with low (L) PALB2 ( p = 0.0018). OS was 13.2 m for p with H-I PALB2 compared to 9.9 for p with L PALB2 ( p = 0.0377). In the univariate analysis, H-I PALB2 was a marker of longer PFS (HR = 0.56, 95% CI, 0.38, 0.80; p = 0.002) and OS (HR = 0.64, 95% CI, 0.41, 0.98; p = 0.0394). In the multivariate analysis, only H-I PALB2 was associated with longer PFS (here HR = 0.56 and p = 0.0022) and OS (HR = 0.61 and p = 0.0343). Among 143 p with data for response and PALB2 expression, 49.5% of p with H-I PALB2 were responders, compared to only 28% with L PALB2 ( p = 0.0131). Conclusions: Higher PALB2 mRNA levels were associated with higher response, longer PFS and OS in NSCLC p treated with docetaxel-cisplatin. However, PALB2 could also be a readout of NRF2 activity and NOTCH signaling, indicative of an increase in cancer stem cells, providing hints for combinatory therapy with gamma secretase inhibitors to prevent the increase of stem-like cells and further improve outcome to docetaxel-cisplatin therapy. Experiments in NSCLC cell lines are ongoing. Legal entity responsible for the study: IGTP, Germans Trias i Pujol Research Institute, Badalona, Barcelona, Spain Funding: FundacióObra Social "La Caixa" Disclosure: All authors have declared no conflicts of interest.
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In vivo study of a novel chemoablative, thermoresponsive hydrogel for intratumoural administration in a murine A549 xenograft model Background: Direct intratumoural (IT) injection of chemotherapeutics into solid tumours has potential to achieve high local concentrations, reducing systemic toxicity and off target side effects. However, this approach is limited by rapid drug clearance from the tumour, resulting in inaccurate and unpredictable dosing. Thermoresponsive hydrogels undergo a characteristic phase change in response to temperature. This allows for minimally invasive administration of a liquid via needle/catheter into the tumour, with localisation and retention following gelation at physiological temperatures. Drug loading of hydrogels facilitates localised, controlled delivery of chemotherapeutics to the tumour, with reduced off site toxicity. Methods: Preclinical assessment of blank and drug loaded formulations was conducted in a murine A549 xenograft model (approved by the RCSI ethics committee). 1 × 10 6 A549-luciferase cells were subcutaneously injected into the right flank of female Athymic NudeFoxn1 nu mice (n = 6 per group). At a tumour volume of approx. 250 mm 3 , 100 μL of hydrogel (blank or drug loaded) or saline was injected IT using a 22G needle. Tumour growth was assessed using callipers and an IVIS ® Spectrum in vivo imaging system over 14 days. On day 14, mice were sacrificed; tumours, liver and kidney excised, fixed and embedded in paraffin for histological and immunohistochemistry studies. Results: Two hours after IT injection, IVIS ® imaging indicated localisation and retention of the hydrogel at injection site. At day 7 and 14 following blank or drug loaded hydrogel treatment, a significant reduction in tumour growth was observed compared to saline ( p = 0.001). Retention of the hydrogel at the tumour site for up to 14 days was observed in ex vivo tumour tissue. No change in welfare scoring was observed during the study, with 100% survival at day 14, indicating treatment did not result in acute off site toxicity. Conclusions: Preliminary preclinical studies have shown the blank and drug loaded hydrogels significantly reduce tumour growth. Further studies are required to fully elucidate the underlying mechanism of action. IT administration of this formulation may represent a potential new adjuvant approach in lung cancer treatment. Legal entity responsible for the study: Royal College of Surgeons in Ireland Funding: Enterprise Ireland Disclosure: All authors have declared no conflicts of interest.
